The Tuberculosis Positive Conversion Rate Among Psoriasis Patients Treated with Adalimumab and Secukinumab: A Single-Center Retrospective Study in China.

Yue XiaoHui ChenQin ZouYiyi WangYuanxia GuJinqiu WangWei YanYiyi Wang

Published in: Dermatology and therapy (2022)

Our data show a relatively high rate of TB conversion among these psoriasis patients after mean treatment duration of 17.13 months. We recommend that, in patients who receive adalimumab, TB be reevaluated after the first 3 months and then monitored semiannually for the next 2 years. For patients treated with secukinumab, annual examination is sufficient.

Keyphrases

mycobacterium tuberculosis
rheumatoid arthritis
ankylosing spondylitis
end stage renal disease
ejection fraction
newly diagnosed
juvenile idiopathic arthritis
prognostic factors
systemic lupus erythematosus
hidradenitis suppurativa
hiv infected
adverse drug